Brachytherapy devices market seen growing to $1.1 billion by 2030

The brachytherapy devices market is projected to rise from $0.8 billion in 2025 to $1.1 billion by 2030, driven by cancer prevalence, new radiation technologies and more oncology investment. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Brachytherapy devices deliver internal radiation directly to tumors, which can limit exposure to healthy tissue. - Rising cancer rates are expanding demand for targeted treatment options and the devices that support them. - The market outlook signals more investment in oncology infrastructure, treatment planning software and minimally invasive cancer care.

What happened: - The global brachytherapy devices market is projected to grow from $0.8 billion in 2025 to $0.85 billion in 2026. - The market is forecast to reach $1.1 billion by 2030, implying a 6.5% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region. - The analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company released the market update on July 29, 2026. - The company posted a free sample report and the full market report.

The details: - Market growth in prior years has been tied to limited device availability, heavy use of low dose rate treatment methods and slow adoption of automated afterloaders. - Other constraints include insufficient oncology infrastructure in developing regions. - The report points to high dose rate and pulsed dose rate brachytherapy technologies as major growth drivers. - Specialized cancer clinics and higher oncology healthcare spending are also supporting demand. - Integration of AI and digital treatment planning software is shaping the next phase of product development. - The report expects broader awareness among healthcare providers about brachytherapy benefits to aid adoption. - Key trends ahead include more HDR brachytherapy use, more minimally invasive procedures, more cancer treatment centers, and more treatment planning and quality assurance tools. - Patient safety and precise radiation delivery are becoming a stronger focus.

Between the lines: - The market forecast suggests brachytherapy is moving from a niche treatment category toward broader clinical adoption as cancer caseloads rise. - Growth depends not only on cancer incidence, but also on whether providers can afford the infrastructure and software needed to use advanced devices. - The Asia-Pacific growth outlook points to unmet oncology demand and expanding healthcare capacity outside mature markets. - In August 2024, Macmillan Cancer Support said more than 3 million people were living with cancer in the UK, with that figure expected to reach 5.3 million by 2040.

What's next: - Device makers are likely to focus on HDR systems, planning software and safety features as hospitals modernize cancer care. - More specialized cancer centers and oncology spending could widen access to brachytherapy in coming years. - The market will likely be shaped by how quickly providers adopt automated systems and digital planning tools.

The bottom line: - Brachytherapy devices remain a small but growing cancer-treatment market, with long-term demand tied to rising cancer prevalence and technology upgrades.